Novel class therapy for IPF

Ended Project Grant Awarded Last action

Award ID
R43HL154868
Recipient
Awarding agency
Obligated
$223,276

Award facts

Assistance listing
93.837 Cardiovascular Diseases Research
Completion date
Originally
Place of performance
Virginia, USA

Award details come from USAspending.gov.

Transactions

Action Obligated Date
Amendment $0
Amendment Novel class therapy for IPF - idiopathic pulmonary fibrosis (IPF) is one of the most fatal lung diseases with high mortality and very limited treatment options.… $0
Original award $223,276

Quick answers

Who received award R43HL154868?

R43HL154868 was awarded to Covenant Therapeutics LLC by National Heart Lung and Blood Institute (National Institutes of Health) on August 25, 2020.

How much is award R43HL154868 worth?

$223,276 has been obligated on R43HL154868.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award